In 2021, SARS-CoV-2 mRNA Vaccine entered Phase Ⅲ clinical trial, and Recombinant SARS-CoV-2 Vaccine (Chimpanzee Adenoviral Vector) which is co-developed with Tsinghua University and Tianjin Medical University entered Phase Ⅰ clinical trial. Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Pichia pastoris) is expected to launch in the near future.
In 2020, the application for manufacturing license of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris) was officially accepted by Chinese National Medical Products Administration (NMPA). Walvax’s SARS-CoV-2 mRNA Vaccine which is co-developed with Chinese Military Academy of Science and Abogen Biosciences entered Phase Ⅰ clinical trial.
In 2019, Walvax identified 10-year development strategy which is to achieve internationalization, Industry 4.0 and import substitution. 13-valent Pneumococcal Polysaccharide Conjugate Vaccine was launched.
In 2018, Group A and C Meningococcal Polysaccharide Vaccine (MPV AC) got Egypt Import Registration Approval and was included in Egypt EPI.
In 2017, Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine were launched, and Group ACYW135 Meningococcal Polysaccharide Vaccine was awarded Halal certification issued by Majelis Ulama Indonesia (MUI).
In 2015, Walvax built partnership with Bill & Melinda Gates Foundation and received USD5 million to expedite HPV vaccines' development process for WHO prequalification.
In 2012, Group A and C Meningococcal Polysaccharide Vaccine and Group ACYW135 Meningococcal Polysaccharide Vaccine were launched, and Haemophilus Influenzae Type b Conjugate Vaccine was officially exported to the Philippines.
In 2010, Walvax was listed on the Growth Enterprise Market (GEM) of Shenzhen Stock Exchange (SZSE). The stock name is abbreviated to “Walvax Biotechnology”, with the stock code of “300142”.
In 2009, Group A and Group C Meningococcal Conjugate Vaccine was launched.
In 2007, Walvax’s first independently developed and industrialized vaccine product, Haemophilus Influenzae Type b Conjugate Vaccine, was launched.
In 2004, Walvax commenced the construction of Yuxi Vaccine Manufacturing Site.